Monopar Therapeutics (NASDAQ:MNPR) Director Sells $659,400.00 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Christopher Starr sold 8,400 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $78.50, for a total value of $659,400.00. Following the sale, the director directly owned 5,173 shares of the company’s stock, valued at $406,080.50. The trade was a 61.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Up 5.3%

Shares of MNPR stock opened at $83.78 on Thursday. Monopar Therapeutics Inc. has a 12 month low of $50.07 and a 12 month high of $124.82. The company has a market cap of $562.16 million, a PE ratio of -38.61 and a beta of 1.50. The business’s 50 day moving average is $105.54 and its two-hundred day moving average is $83.33.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. As a group, equities analysts expect that Monopar Therapeutics Inc. will post -2.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on MNPR shares. UBS Group set a $125.00 price target on Monopar Therapeutics in a research report on Thursday, July 23rd. Cantor Fitzgerald cut Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price objective for the stock from $109.00 to $119.00 in a research report on Thursday, August 13th. Barclays restated an “overweight” rating and set a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. BTIG Research raised their target price on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Zacks Research downgraded Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $122.00.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds have recently made changes to their positions in MNPR. Bank of New York Mellon Corp bought a new position in Monopar Therapeutics during the second quarter valued at about $7,124,000. Siren L.L.C. lifted its position in shares of Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the period. Bank of America Corp DE grew its holdings in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Monopar Therapeutics during the first quarter valued at approximately $3,458,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.